Catalog No.:AA008TAZ

1035270-39-3 | Azd4547

Name: Name:Azd4547
Brand: AABLOCKS
SKU: AA008TAZ
Availability: InStock
Rating: 90 (10 reviews)

Pack Size

Purity

Availability

Price(USD)

Quantity

1mg

98%

in stock

$7.00 $5.00

- +

5mg

98%

in stock

$15.00 $11.00

- +

10mg

98%

in stock

$23.00 $16.00

- +

250mg

98%

in stock

$180.00 $126.00

- +

Technical Information
Properties
Downstream Synthesis Route
Literature
Request for Quotation
Download SDS

Technical Information
Properties
Downstream Synthesis Route
Literature

Technical Information

Catalog Number:

AA008TAZ

Chemical Name:

Azd4547

CAS Number:

1035270-39-3

Molecular Formula:

C26H33N5O3

Molecular Weight:

463.5719

MDL Number:

MFCD22580423

SMILES:

COc1cc(CCc2[nH]nc(c2)NC(=O)c2ccc(cc2)N2C[C@H](C)N[C@@H](C2)C)cc(c1)OC

Properties

Computed Properties

Complexity:

622

Covalently-Bonded Unit Count:

Defined Atom Stereocenter Count:

Heavy Atom Count:

Hydrogen Bond Acceptor Count:

Hydrogen Bond Donor Count:

Rotatable Bond Count:

XLogP3:

3.9

Downstream Synthesis Route

24566-79-8

1035270-39-3

N-(5-(3,5-dimethoxyphenethyl)-1H-pyrazol-3-yl)-4-((3S,5R)-4-(6-(1,3-dioxoisoindolin-2-yl)hexyl)-3,5-dimethylpiperazin-1-yl)benzamide

[1]InternationalJournalofNanomedicine,2017,vol.12,p.5345-5357

1035270-39-3

2-(14-bromo-3,6,9,9,12-tetraoxatetradecyl)isoindoline-1,3-dione

C44H56N6O9

[1]Patent:KR101820381,2018,B1.Locationinpatent:Paragraph0067-0069

20767-04-8

1035270-39-3

[1]Patent:CN111072638,2020,A

234082-05-4

2615357-33-8

1035270-39-3

[1]CurrentPatentAssignee:ABBISKOTHERAPEUTICSCO.,LTD.;WUXIHEYUBIOMEDICALTECH-CN115819239,2023,ALocationinpatent:Paragraph0088;0166-0170

Literature

Title: Design, synthesis and biological evaluation of novel FGFR inhibitors bearing an indazole scaffold.

Journal: Organic & biomolecular chemistry 20150728

Title: Transforming fusions of FGFR and TACC genes in human glioblastoma.

Journal: Science (New York, N.Y.) 20120907

Title: AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family.

Journal: Cancer research 20120415

Title: Gavine PR, et al. AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res, 2012, 72(8), 2045-2056.

Quotation Request

Company Name:

Contact Person:

Email:

Quantity Required:

Country:

Additional Info:

SDS